Literature DB >> 9501077

Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly.

U K von Schwedler1, T L Stemmler, V Y Klishko, S Li, K H Albertine, D R Davis, W I Sundquist.   

Abstract

After budding, the human immunodeficiency virus (HIV) must 'mature' into an infectious viral particle. Viral maturation requires proteolytic processing of the Gag polyprotein at the matrix-capsid junction, which liberates the capsid (CA) domain to condense from the spherical protein coat of the immature virus into the conical core of the mature virus. We propose that upon proteolysis, the amino-terminal end of the capsid refolds into a beta-hairpin/helix structure that is stabilized by formation of a salt bridge between the processed amino-terminus (Pro1) and a highly conserved aspartate residue (Asp51). The refolded amino-terminus then creates a new CA-CA interface that is essential for assembling the condensed conical core. Consistent with this model, we found that recombinant capsid proteins with as few as four matrix residues fused to their amino-termini formed spheres in vitro, but that removing these residues refolded the capsid amino-terminus and redirected protein assembly from spheres to cylinders. Moreover, point mutations throughout the putative CA-CA interface blocked capsid assembly in vitro, core assembly in vivo and viral infectivity. Disruption of the conserved amino-terminal capsid salt bridge also abolished the infectivity of Moloney murine leukemia viral particles, suggesting that lenti- and oncoviruses mature via analogous pathways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9501077      PMCID: PMC1170503          DOI: 10.1093/emboj/17.6.1555

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  63 in total

1.  Molecular recognition in the HIV-1 capsid/cyclophilin A complex.

Authors:  S Yoo; D G Myszka; C Yeh; M McMurray; C P Hill; W I Sundquist
Journal:  J Mol Biol       Date:  1997-06-27       Impact factor: 5.469

2.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Evolution of retroposons by acquisition or deletion of retrovirus-like genes.

Authors:  M A McClure
Journal:  Mol Biol Evol       Date:  1991-11       Impact factor: 16.240

4.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

5.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

Authors:  U von Schwedler; J Song; C Aiken; D Trono
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.

Authors:  J B Jowett; D J Hockley; M V Nermut; I M Jones
Journal:  J Gen Virol       Date:  1992-12       Impact factor: 3.891

8.  Zinc- and sequence-dependent binding to nucleic acids by the N-terminal zinc finger of the HIV-1 nucleocapsid protein: NMR structure of the complex with the Psi-site analog, dACGCC.

Authors:  T L South; M F Summers
Journal:  Protein Sci       Date:  1993-01       Impact factor: 6.725

9.  Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions.

Authors:  M Piotto; V Saudek; V Sklenár
Journal:  J Biomol NMR       Date:  1992-11       Impact factor: 2.835

10.  Determination of the structure of the nucleocapsid protein NCp7 from the human immunodeficiency virus type 1 by 1H NMR.

Authors:  N Morellet; N Jullian; H De Rocquigny; B Maigret; J L Darlix; B P Roques
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

View more
  195 in total

1.  Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab.

Authors:  C Berthet-Colominas; S Monaco; A Novelli; G Sibaï; F Mallet; S Cusack
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

2.  Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions.

Authors:  J B Bowzard; J W Wills; R C Craven
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes.

Authors:  L S Ehrlich; T Liu; S Scarlata; B Chu; C A Carter
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

5.  Nucleic acid-independent retrovirus assembly can be driven by dimerization.

Authors:  Marc C Johnson; Heather M Scobie; Yu May Ma; Volker M Vogt
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution.

Authors:  Florian K M Schur; Wim J H Hagen; Michaela Rumlová; Tomáš Ruml; Barbara Müller; Hans-Georg Kräusslich; John A G Briggs
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

7.  Role of the Rous sarcoma virus p10 domain in shape determination of gag virus-like particles assembled in vitro and within Escherichia coli.

Authors:  S M Joshi; V M Vogt
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  The TY3 Gag3 spacer controls intracellular condensation and uncoating.

Authors:  Kristina Clemens; Liza Larsen; Min Zhang; Yurii Kuznetsov; Virginia Bilanchone; Arlo Randall; Adam Harned; Rhonda Dasilva; Kunio Nagashima; Alexander McPherson; Pierre Baldi; Suzanne Sandmeyer
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

9.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy.

Authors:  Daniel R Larson; Yu May Ma; Volker M Vogt; Watt W Webb
Journal:  J Cell Biol       Date:  2003-09-29       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.